Trial Profile
Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Treosulfan (Primary) ; Cisplatin; Cytarabine; Dacarbazine; Paclitaxel
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms ChemoSensMM
- 19 Oct 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 07 Nov 2008 New trial record.